Taken together, all above data indicate that after blocking K-RasG13D mutation, ERK inhibitor has attenuated its suppressive effect on HCT-116 cells but not much in HT-29 cells, that implies that K-RasG13D mutation works via the ERK pathway to promote major cancer stemness in HCT-116 cells. This evidence concerns the gene MAPK1 and cancer.